Swedish drugmaker Sobi agreed to acquire Arthrosi Therapeutics for $950 million in cash with up to $550 million in clinical, regulatory, and sales milestones to add pozdeutinurad (AR882), a Phase III URAT1 inhibitor for progressive gout. Sobi said it will fund the upfront via debt facilities and expects the transaction to close in H1 2026. Two fully enrolled Phase III studies are expected to report data in 2026, and Sobi framed the asset as a potential therapy for patients who fail first-line urate-lowering therapy. Both companies highlighted continuity plans and integration of Arthrosi’s team into Sobi’s commercial organization.